Cutler Group LP Bio N Tech Se Put Options Transaction History

Cutler Group LP

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2022 Feb 07, 2023	SELL	$118.43 - $186.05 $225,017 - $353,495	-1,900 Reduced 27.54%	5,000 $95,000
Q3 2022 Oct 25, 2022	SELL	$127.65 - $183.11 $102,120 - $146,488	-800 Reduced 10.39%	6,900 $178,000
Q2 2022 Aug 04, 2022	SELL	$123.25 - $186.24 $5.83 Million - $8.81 Million	-47,300 Reduced 86.0%	7,700 $244,000
Q1 2022 Apr 14, 2022	BUY	$126.25 - $231.85 $808,000 - $1.48 Million	6,400 Added 13.17%	55,000 $3.08 Million
Q4 2021 Jan 18, 2022	BUY	$216.64 - $362.52 $8.67 Million - $14.5 Million	40,000 Added 465.12%	48,600 $2.08 Million
Q2 2021 Jul 19, 2021	SELL	$113.32 - $241.49 $169,980 - $362,235	-1,500 Reduced 14.85%	8,600 $24,000
Q1 2021 Apr 26, 2021	SELL	$85.73 - $119.5 $385,785 - $537,750	-4,500 Reduced 30.82%	10,100 $165,000
Q4 2020 Jan 21, 2021	BUY	$72.71 - $129.54 $276,298 - $492,251	3,800 Added 35.19%	14,600 $375,000
Q3 2020 Oct 27, 2020	SELL	$57.81 - $104.17 $294,831 - $531,267	-5,100 Reduced 32.08%	10,800 $47,000
Q2 2020 Jul 22, 2020	BUY	$38.58 - $66.74 $613,422 - $1.06 Million	15,900 New	15,900 $67,000

357

38.3M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $27.4B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.